Of the 721 MDR P. aeruginosa sent to CFASS for extended antimicrobial susceptibility testing over a 20-year period (2001–2020), one-tenth of the patient-unique isolates were randomly selected for this study. These isolates, stored in the bacterial preservation system MICROBANKTM (Pro-Lab Diagnostics, Richmond Hill, ON, Canada) at −80 °C, were plated onto Mueller-Hinton (MH) agar (Oxoid Ltd., Basingstoke, UK) and were identified using a Vitek® MS (BioMérieux, Inc., Durham, NC, USA). Isolates were tested by CFASS and were classified as multidrug-resistant if there was acquired non-susceptibility to at least one agent in the ≥3 antimicrobial group [22 (link)]. The media used for minimum inhibitory concentration (MIC) and synergy testing included Mueller-Hinton agar and cation-adjusted Mueller-Hinton II broth (CAMHB). P. aeruginosa ATCC 27853 was used as a quality control strain to validate the MIC values.
Free full text: Click here